Publication:
Repositioning of the global epicentre of non-optimal cholesterol

dc.contributor.authorNCD Risk Factor Collaboration (NCD-RisC)
dc.contributor.authorFrontera-Juan, Guillem
dc.contributor.authorRamos-Asensio, Rafael
dc.contributor.authorReigada Mendez, Rebeca
dc.contributor.authorRomaguera, Dora
dc.contributor.authorTorrent Quetglas, Maties
dc.date.accessioned2024-09-13T09:15:50Z
dc.date.available2024-09-13T09:15:50Z
dc.date.issued2020-06-04
dc.description.abstractHigh blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.en
dc.description.sponsorshipThis study was funded by a Wellcome Trust (Biomedical Resource & Multi-User Equipment grant 01506/Z/13/Z) and the British Heart Foundation (Centre of Research Excellence grant RE/18/4/34215). C.T. was supported by a Wellcome Trust Research Training Fellowship (203616/Z/16/Z). The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.es_ES
dc.format.number7810es_ES
dc.format.page73-77es_ES
dc.format.volume582es_ES
dc.identifier.citationTaddei C, Zhou B, Bixby H, Carrillo-Larco RM, Danaei G, Jackson RT, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020 Jun 04;582(7810):73-7. Epub 2020 Jun 3.en
dc.identifier.doi10.1038/s41586-020-2338-1
dc.identifier.e-issn1476-4687es_ES
dc.identifier.issn0028-0836
dc.identifier.journalNaturees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/10387
dc.identifier.pubmedID32494083es_ES
dc.identifier.puiL2005144534
dc.identifier.scopus2-s2.0-85085994877
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23018
dc.identifier.wos562463000002
dc.language.isoengen
dc.publisherNature Publishing Group
dc.relation.publisherversionhttps://dx.doi.org/10.1038/s41586-020-2338-1en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.decsIsquemia Miocárdica*
dc.subject.decsAccidente Cerebrovascular*
dc.subject.decsLDL-Colesterol*
dc.subject.decsFemenino*
dc.subject.decsHDL-Colesterol*
dc.subject.decsAdolescente*
dc.subject.decsMasculino*
dc.subject.decsHumanos*
dc.subject.decsPersona de Mediana Edad*
dc.subject.decsAdulto Joven*
dc.subject.decsTeorema de Bayes*
dc.subject.decsAnciano*
dc.subject.decsAnciano de 80 o más Años*
dc.subject.decsHipercolesterolemia*
dc.subject.decsInternacionalidad*
dc.subject.decsTriglicéridos*
dc.subject.decsAdulto*
dc.subject.meshTriglycerides*
dc.titleRepositioning of the global epicentre of non-optimal cholesterolen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication301fb00e-338e-4f8c-beaa-f9d8f4fefcc0
relation.isPublisherOfPublication.latestForDiscovery301fb00e-338e-4f8c-beaa-f9d8f4fefcc0

Files